Condition
Sedation Complication
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownRemifentanil Target Controlled Infusion Versus Standard of Care for Conscious Sedation During EBUS-TBNANCT06033729 · 2021-09-20
COMPLETEDEffect of HFNO on Spontaneous Ventilation in Obese Patients During Analgo-sedation for VitrectomyNCT04049240 · 2019-08-01
UNKNOWNEffect of Sedation Strategy on Duration Mechanical Ventilation in Patient After Cardiac SurgeryNCT05451121 · 2017-07-01
COMPLETEDCommon interventions
PropofolDRUG2Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2DEVICE1Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2DEVICE1Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2DEVICE1Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2DEVICE1Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2DEVICE1Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2DEVICE1DexmedetomidineDRUG1FentanylDRUG1Midazolam injectionDRUG1Propofol and dexmedetomidineDRUG1Remifentanil TCIDRUG1
Leading sponsors
Trial status mix
COMPLETED2
UNKNOWN1
Phase mix
NA3
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.